4 years ago

Alchemab Therapeutics Secures £60M Series A Funding for Drug Discovery Platform

  • Alchemab Therapeutics, a Cambridge, England, UK-based biotech company developing novel products for patients with diseases by harnessing naturally protective antibodies, has raised £60m ($82m) in Series A funding led by RA Capital Management

  • The round also included participation from Lightstone Ventures, Data Collective VC (DCVC), DHVC, SV Health Investors and the Dementia Discovery Fund

  • The company intends to use the funds to advance its target-agnostic drug discovery platform

  • Alchemab was founded in 2019 and is led by Alex Leech, CEO, and Dr Jane Osbourn OBE, CSO

  • The company's platform enables the identification of novel drug targets and therapeutics based on patient B-cell antibody repertoires.

      • ProblemHealthcare

      "identifying novel drug targets and therapeutics for patients with diseases by harnessing naturally protective antibodies"

      Solution

      "developing a target-agnostic drug discovery platform that uses patient B-cell antibody repertoires to identify convergent protective antibody responses in individuals susceptible to specific diseases"

      Covered on